NYSE - Nasdaq Real Time Price USD

Medtronic plc (MDT)

82.84 +0.08 (+0.10%)
At close: May 10 at 4:00 PM EDT
82.03 -0.81 (-0.98%)
After hours: May 10 at 7:51 PM EDT
Loading Chart for MDT
DELL
  • Previous Close 82.76
  • Open 83.00
  • Bid 82.03 x 1200
  • Ask 84.00 x 800
  • Day's Range 82.28 - 83.06
  • 52 Week Range 68.84 - 91.00
  • Volume 4,216,992
  • Avg. Volume 6,193,229
  • Market Cap (intraday) 109.997B
  • Beta (5Y Monthly) 0.80
  • PE Ratio (TTM) 26.30
  • EPS (TTM) 3.15
  • Earnings Date May 23, 2024
  • Forward Dividend & Yield 2.76 (3.33%)
  • Ex-Dividend Date Mar 21, 2024
  • 1y Target Est 94.00

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and products. The company's Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases, as well as products in the fields of minimally invasive gastrointestinal and hepatologic diagnostics and therapies, patient monitoring, airway management and ventilation therapies, and renal disease. Its Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The company's Diabetes Operating Unit segment offers insulin pumps and consumables, continuous glucose monitoring systems, smart insulin pen systems, and consumables and supplies. The company was founded in 1949 and is headquartered in Dublin, Ireland.

www.medtronic.com

95,000

Full Time Employees

April 28

Fiscal Year Ends

Recent News: MDT

Performance Overview: MDT

Trailing total returns as of 5/10/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

MDT
1.39%
S&P 500
9.49%

1-Year Return

MDT
4.45%
S&P 500
26.79%

3-Year Return

MDT
28.59%
S&P 500
23.39%

5-Year Return

MDT
7.24%
S&P 500
81.93%

Compare To: MDT

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: MDT

Valuation Measures

Annual
As of 5/10/2024
  • Market Cap

    110.00B

  • Enterprise Value

    126.86B

  • Trailing P/E

    26.30

  • Forward P/E

    15.15

  • PEG Ratio (5yr expected)

    1.57

  • Price/Sales (ttm)

    3.42

  • Price/Book (mrq)

    2.12

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    13.00%

  • Return on Assets (ttm)

    4.23%

  • Return on Equity (ttm)

    8.17%

  • Revenue (ttm)

    32.32B

  • Net Income Avi to Common (ttm)

    4.2B

  • Diluted EPS (ttm)

    3.15

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    8.32B

  • Total Debt/Equity (mrq)

    48.43%

  • Levered Free Cash Flow (ttm)

    5.51B

Research Analysis: MDT

Company Insights: MDT

Research Reports: MDT

People Also Watch